These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 24525237)

  • 1. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
    Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
    Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type RAS: keeping mutant RAS in CHK.
    Anastassiadis T; Brown EJ
    Cancer Cell; 2014 Feb; 25(2):137-8. PubMed ID: 24525230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
    Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
    Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
    Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
    Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response.
    Grabocka E; Commisso C; Bar-Sagi D
    Clin Cancer Res; 2015 Mar; 21(6):1243-7. PubMed ID: 25424849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
    Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
    Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.
    Emile JF; Diamond EL; Hélias-Rodzewicz Z; Cohen-Aubart F; Charlotte F; Hyman DM; Kim E; Rampal R; Patel M; Ganzel C; Aumann S; Faucher G; Le Gall C; Leroy K; Colombat M; Kahn JE; Trad S; Nizard P; Donadieu J; Taly V; Amoura Z; Abdel-Wahab O; Haroche J
    Blood; 2014 Nov; 124(19):3016-9. PubMed ID: 25150293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
    Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
    PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo.
    Mallucci L; Shi DY; Davies D; Jordan P; Nicol A; Lotti L; Mariani-Costantini R; Verginelli F; Wells V; Zicha D
    Mol Cancer Ther; 2012 Sep; 11(9):1884-93. PubMed ID: 22752425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
    Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
    Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.
    Yellen P; Foster DA
    Cancer Lett; 2014 Oct; 353(2):258-63. PubMed ID: 25086185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.